{"id":"W4241752191","doi":"10.1093/annonc/mdv338.01","title":"Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Regorafenib; Internal medicine; Clinical endpoint; Hazard ratio; GiST; Randomization; Placebo; Gastroenterology; Randomized controlled trial; Response Evaluation Criteria in Solid Tumors; Sunitinib; Surrogate endpoint; Progression-free survival; Phases of clinical research; Surgery; Confidence interval; Cancer; Clinical trial; Colorectal cancer; Pathology; Chemotherapy; Stromal cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000995002,0.001631794,0.002245269,0.0002579068,0.0002977432,0.0009368687,0.0008286482,0.001044482,0.008126569],"category_scores_gemma":[0.001115399,0.0004829947,0.001599393,0.0003228613,0.001229123,0.0009897428,0.0005807711,0.00278816,0.001722843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001003194,"about_ca_system_score_gemma":0.001277958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001737465,"about_ca_topic_score_gemma":0.00516469,"domain_scores_codex":[0.9997042,0.0001443057,0.00001195368,0.00006525535,0.00001476959,0.0000595846],"domain_scores_gemma":[0.9994664,0.00008988382,0.0001248195,0.00006317312,0.00002258357,0.0002330358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9541063,0.003647379,0.001993681,0.00058112,0.001106793,0.0001058194,0.00007444176,0.00185662,0.003484541,0.0003859501,0.00624524,0.02641217],"study_design_scores_gemma":[0.9694174,0.02581655,0.00180662,0.00001919824,0.0002217981,0.00008718071,0.00002944877,0.0003986775,0.0002236326,0.0003449085,0.001622326,0.00001239475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784188,0.004214664,0.00106514,0.002340143,0.0008254601,0.002874741,0.004732253,0.0004072027,0.005121551],"genre_scores_gemma":[0.9761362,0.002780224,0.002625411,0.002634872,0.000332452,0.003758217,0.005343436,0.00007634973,0.006312812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008126569,"threshold_uncertainty_score":0.02718604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1401956859182169,"score_gpt":0.4138674545474313,"score_spread":0.2736717686292144,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}